The brokerage expects supplies for GLP-1 molecules to begin in FY27, while two key oral peptide opportunities, Enlicitide and Icotrokinra, could start contributing from calendar year 2027.
The brokerage expects supplies for GLP-1 molecules to begin in FY27, while two key oral peptide opportunities, Enlicitide and Icotrokinra, could start contributing from calendar year 2027.
<iframe src="https://hindustansphere.com/embed/cluster/d45b00c97d5dabb47b3faa858c49866acc140c53" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Citi Picks Divi's As Top India Pharma Bet, Sees Peptide Pipeline Driving Next Leg Of Growth"></iframe>
